153 related articles for article (PubMed ID: 33733758)
21. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
22. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Linger RM; Keating AK; Earp HS; Graham DK
Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.
Danielli SG; Wurth J; Morice S; Kisele S; Surdez D; Delattre O; Bode PK; Wachtel M; Schäfer BW
Mol Cancer Ther; 2024 Jun; 23(6):864-876. PubMed ID: 38471796
[TBL] [Abstract][Full Text] [Related]
24. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
25. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
26. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
27. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
28. Recent discovery and development of AXL inhibitors as antitumor agents.
Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
[TBL] [Abstract][Full Text] [Related]
29. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors.
Tang H; Yang J; Shen DR; Calambur D; Witmer M; Wu S; Carpenter B; Zhang Y; Gao M; Constantine K; Zhang L; Cvijic ME
Assay Drug Dev Technol; 2014; 12(1):80-6. PubMed ID: 24547742
[TBL] [Abstract][Full Text] [Related]
30. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
31. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis.
Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831142
[TBL] [Abstract][Full Text] [Related]
32. Optimization of an Imidazo[1,2-
McCoull W; Boyd S; Brown MR; Coen M; Collingwood O; Davies NL; Doherty A; Fairley G; Goldberg K; Hardaker E; He G; Hennessy EJ; Hopcroft P; Hodgson G; Jackson A; Jiang X; Karmokar A; Lainé AL; Lindsay N; Mao Y; Markandu R; McMurray L; McLean N; Mooney L; Musgrove H; Nissink JWM; Pflug A; Reddy VP; Rawlins PB; Rivers E; Schimpl M; Smith GF; Tentarelli S; Travers J; Troup RI; Walton J; Wang C; Wilkinson S; Williamson B; Winter-Holt J; Yang D; Zheng Y; Zhu Q; Smith PD
J Med Chem; 2021 Sep; 64(18):13524-13539. PubMed ID: 34478292
[TBL] [Abstract][Full Text] [Related]
33. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
34. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
[TBL] [Abstract][Full Text] [Related]
35. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.
Feneyrolles C; Guiet L; Singer M; Van Hijfte N; Daydé-Cazals B; Fauvel B; Chevé G; Yasri A
Bioorg Med Chem Lett; 2017 Feb; 27(4):862-866. PubMed ID: 28094183
[TBL] [Abstract][Full Text] [Related]
36. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
[TBL] [Abstract][Full Text] [Related]
37. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
38. Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor.
Zheng B; Guo H; Ma N; Ni Y; Xu J; Li L; Hao P; Ding K; Li Z
Chem Asian J; 2018 Sep; 13(18):2601-2605. PubMed ID: 29939481
[TBL] [Abstract][Full Text] [Related]
39. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
40. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]